SCHEMBL975169

SCHEMBL975169

O=C(O)c1cccc(NS(=O)(=O)CC2CN(C(c3ccc(Cl)cc3)c3ccc(Cl)cc3)C2)c1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
ACLY P53396 3/20 0.38
SLC6A9 P48067 2/20 0.38
SCN9A Q15858 4/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
FABP4 P15090 1/20 0.36
SERPINE1 P05121 1/20 0.36
CACNA2D1 P54289 6/20 0.36
CACNB1 Q02641 6/20 0.36
CACNA1B Q00975 5/20 0.36
CACNA1C Q13936 4/20 0.36
CACNA1G O43497 1/20 0.36
CNR1 P21554 1/20 0.36
SCN7A Q01118 1/20 0.35
SCN5A Q14524 1/20 0.35
CACNA1A O00555 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL974851 0.89 SLC6A9 (0.38) SLC6A9SCN9AKDM4EALDH1A1HPGD
SCHEMBL977199 0.85 KDM4E (0.36) SLC6A9SCN9AKDM4EALDH1A1HPGD
SCHEMBL977068 0.84 SCN9A (0.34) SLC6A9SCN9ASCN7ASCN5A
SCHEMBL977175 0.82 FABP4 (0.40) SLC6A9SCN9AFABP4SCN7ASCN5A
SCHEMBL976064 0.82 ACLY (0.43) MEN1KMT2AACLYSLC6A9SCN9A
SCHEMBL977461 0.79 MEN1 (0.44) MEN1KMT2ASLC6A9KDM4EALDH1A1
SCHEMBL974202 0.77 WDR5 (0.41) SLC6A9SCN9AFABP4CACNA2D1CACNB1
SCHEMBL27965454 0.77 KDM4E (0.36) SLC6A9KDM4EALDH1A1HPGDHSD17B10
SCHEMBL975244 0.76 WDR5 (0.44) MEN1KMT2ASLC6A9FABP4CACNA2D1
SCHEMBL975170 0.74 SLC6A9 (0.38) MEN1KMT2ASLC6A9SCN9ACACNA2D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI (FR) 2013-09-12 US claimed
EP-2234966-B1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI SA (FR) 2013-09-11 EP claimed
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI-AVENTIS (FR) 2011-01-13 US claimed
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI (FR) 2013-09-12 US disclosed
US-8445478-B2 Azetidine derivatives, their preparation and their application in therapy SANOFI (FR) 2013-05-21 US disclosed
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY SANOFI-AVENTIS (FR) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237513-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY QDPR, AZI2, ADRA1B MEN1 1111/4885KMT2A 2003/4885ACLY 2120/4885
US-20110009377-A1 AZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPY QDPR, AZI2, ADRA1B MEN1 1111/4885KMT2A 2003/4885ACLY 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.